PCDHB12

Across TCGA pan-cancer cohorts, PCDHB12 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated PCDHB12 data layer compared with 10 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PCDHB12 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHB12 expression acts as an unfavorable survival marker, although some lineages such as KIRC and OV show a favorable association.

BLCA, KIRC, and OV are the cancer types where PCDHB12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.246	0.444	<.001	113	view →
KIRC	DFS	Median	All	0.943	0.784	<.001	60	view →
OV	OS	Median	IV	0.521	0.242	<.001	42	view →
STAD	OS	Quartile	All	0.338	0.617	.003	40	view →
CESC	DFS	Median	All	0.758	0.882	<.001	22	view →
SARC	OS	Quartile	All	0.370	0.758	.001	20	view →
LGG	OS	Median	All	0.762	0.856	.005	18	view →
THCA	OS	Median	III,IV	0.945	1.000	.005	15	view →
PAAD	OS	Quartile	II,III,IV	0.613	0.358	.008	15	view →
ACC	OS	Median	IV	0.287	0.799	.006	14	view →
KICH	DFS	Tertile	All	0.747	1.000	.007	12	view →
SKCM	DFS	Median	All	0.673	0.545	.002	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

PCDHB12–BLCA (DFS)

Open the BLCA breakdown →